$47.87
Today
as of Aug 5, 16:54 ET
Last 30 days
Recent Press Releases & News
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
Scholar Rock Holding (SRRK) Pulls Back Following A Strong Run, Is It Trading At A Discount?
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
Overview
52-week range
$27
$52
83% of range
Avg surprise (last 3)
-18.7%
Avg reaction (last 2)
-2.1%
0% positive
Latest IV / EM
81%
EM ±13.5% · $50 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.83 | $-0.82 | -1.2% | -23.9% | -1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.90 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.98 | $-0.66 | -48.5% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.67 | $-0.63 | -6.3% | — | -2.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.66 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.60 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.59 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.53 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.47 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | BMO | -$0.84 | -$0.98 | +14.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-102M | — | $-104M | $-112M | $-77M | — | $-65M | $-59M |
| Net income | $-106M | — | $-102M | $-110M | $-75M | — | $-64M | $-59M |
| EPS (diluted) | $-0.83 | — | $-0.90 | $-0.98 | $-0.67 | — | $-0.66 | $-0.60 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $431M | $324M | $287M | $153M | $138M | $178M | $76M | $93M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $515M | $385M | $391M | $319M | $385M | $451M | $153M | $199M |
| Total assets | $535M | $404M | $412M | $340M | $408M | $475M | $179M | $227M |
| Long-term debt | $197M | $100M | $100M | $50M | $50M | $50M | $50M | $48M |
| Total liabilities | $259M | $159M | $167M | $107M | $95M | $106M | $100M | $93M |
| Total equity | $276M | $245M | $245M | $233M | $312M | $369M | $79M | $134M |